Evidence map›Paper›PMID 41579860›Full record

ArticleCell reports. Medicine2026

CAR-T cells with the CD38

Takashi Mikami, Itaru Kato, Mara Anais Llamas-Covarrubias, Hidefumi Hiramatsu, Yoshinori Uchihara, Takaya Mitsuyoshi, Toshio Kitawaki, Satoshi Saida, Katsutsugu Umeda, Seishi Ogawa and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Takashi MikamiDepartment of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan.
Itaru KatoDepartment of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan. Electronic address: itarkt@kuhp.kyoto-u.ac.jp.
Mara Anais Llamas-CovarrubiasLaboratory of Human Single Cell Immunology, Immunology Frontier Research Center (IFReC), The University of Osaka, Suita 565-0871, Osaka, Japan.
Hidefumi HiramatsuDepartment of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan; Department of Pediatrics, Kindai University Faculty of Medicine, Sakai 590-0197, Osaka, Japan.
Yoshinori UchiharaDepartment of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan.
Takaya MitsuyoshiDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto 606-8397, Japan.
Toshio KitawakiDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto 606-8397, Japan.
Satoshi SaidaDepartment of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan.
Katsutsugu UmedaDepartment of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan.
Seishi OgawaDepartment of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto 606-8501, Japan; Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto 606-8501, Japan.
Akifumi Takaori-KondoDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto 606-8397, Japan.
James Badger WingLaboratory of Human Single Cell Immunology, Immunology Frontier Research Center (IFReC), The University of Osaka, Suita 565-0871, Osaka, Japan; Human Single Cell Immunology Team, Center for Infectious Disease Education and Research (CiDER), The University of Osaka, Suita 565-0871, Osaka, Japan; Center for Advanced Modalities and DDS (CAMaD), The University of Osaka, Suita 565-0871, Osaka, Japan.
Junko TakitaDepartment of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan. Electronic address: jtakita@kuhp.kyoto-u.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anti-CD19 chimeric antigen receptor T cell (CAR-T) therapy is highly effective for B cell precursor acute lymphoblastic leukemia (BCP-ALL); however, approximately half of the patients relapse. Thus, there is an urgent need to identify factors that improve efficacy. This study enrolls 19 patients with BCP-ALL (16 children and 3 young adults) who receive tisagenlecleucel. Infusion products, peripheral blood, and bone marrow samples are obtained before and after CAR-T cell infusion. Single-cell analysis reveals that central memory CAR

Indexed as

ADP-ribosyl Cyclase 1HLA-DR AntigensImmunotherapy, AdoptivePrecursor B-Cell Lymphoblastic Leukemia-LymphomaReceptors, Antigen, T-CellT-LymphocytesAdolescentAdultChildChild, PreschoolFemaleHumansMalePhenotypeYoung AdultADP-ribosyl Cyclase 1HLA-DR AntigensReceptors, Antigen, T-Celltisagenlecleucelacute lymphoblastic leukemiaadenosineanti-CD19 CAR-T therapyCD38CD73tisagenlecleucel

Identifiers

PMID41579860
PMCPMC12923955

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.